LivaNova to wind down Advanced Circulatory Support business unit

LivaNova is a medical device company that specializes in the development and sale of advanced cardiac devices. In recent years, the company has been facing challenges in its Advanced Circulatory Support (ACS) business unit, which focuses on the development and sale of extracorporeal life support (ECLS) devices used to treat patients with severe heart failure.

As a result, LivaNova has announced plans to wind down its ACS business unit. This decision was made after careful consideration of the market conditions and the company's strategic priorities. The company believes that the ACS business unit is no longer aligned with its core competencies and that it would be better served by focusing on other areas of the business.

LivaNova has been in the medical device industry for over 20 years and has a strong track record of innovation and success. The company's mission is to improve the lives of patients with cardiac diseases by developing and providing advanced cardiac devices that are safe, effective, and easy to use.

The decision to wind down the ACS business unit is expected to have a minimal impact on LivaNova's overall financial performance. The company will continue to focus on its core cardiac device business, which includes products such as pacemakers, defibrillators, and cardiac monitoring devices.

LivaNova has not provided any specific timeline for the wind down of the ACS business unit, but it is expected to be completed over the next several months. The company will work closely with its customers and partners to ensure a smooth transition and minimize any disruption to patient care.